OBJECTIVE: This study aimed to validate the Computerized UCSD Performance-Based Skills Assessment (C-UPSA), a newly developed scale for assessing functional capacity in patients with schizophrenia. METHODS: The C-UPSA was administered to 21 middle-aged and older adults with schizophrenia and 20 healthy comparison (HC) subjects. Schizophrenia participants also completed the original UPSA and a symptom inventory (during a separate visit), and cognitive functioning was assessed in both groups using a brief neuropsychological screening battery. RESULTS: The C-UPSA total score was significantly correlated with UPSA total scores, and the magnitude of the correlation was comparable to the test-retest reliability of the original UPSA. The C-UPSA was also significantly correlated with UPSA-Brief scores and neuropsychological status among schizophrenia participants. Furthermore, the schizophrenia group scored significantly lower than the HCs on the C-UPSA. ROC curves were generated to determine the optimal C-UPSA value for discriminating between the two groups, with results indicating an optimal cutoff of 75, which is consistent with the derived cutoff from the original UPSA. The C-UPSA identified persons with schizophrenia with 95% accuracy. CONCLUSIONS: The C-UPSA appears to be highly related to the original UPSA. It has several advantages over the standard version, including increased portability, decreased administration time, and minimized examiner impact on participant performance. Future research would benefit from establishing this test as a clinical and research tool to effectively assess functional capacity.
OBJECTIVE: This study aimed to validate the Computerized UCSD Performance-Based Skills Assessment (C-UPSA), a newly developed scale for assessing functional capacity in patients with schizophrenia. METHODS: The C-UPSA was administered to 21 middle-aged and older adults with schizophrenia and 20 healthy comparison (HC) subjects. Schizophreniaparticipants also completed the original UPSA and a symptom inventory (during a separate visit), and cognitive functioning was assessed in both groups using a brief neuropsychological screening battery. RESULTS: The C-UPSA total score was significantly correlated with UPSA total scores, and the magnitude of the correlation was comparable to the test-retest reliability of the original UPSA. The C-UPSA was also significantly correlated with UPSA-Brief scores and neuropsychological status among schizophreniaparticipants. Furthermore, the schizophrenia group scored significantly lower than the HCs on the C-UPSA. ROC curves were generated to determine the optimal C-UPSA value for discriminating between the two groups, with results indicating an optimal cutoff of 75, which is consistent with the derived cutoff from the original UPSA. The C-UPSA identified persons with schizophrenia with 95% accuracy. CONCLUSIONS: The C-UPSA appears to be highly related to the original UPSA. It has several advantages over the standard version, including increased portability, decreased administration time, and minimized examiner impact on participant performance. Future research would benefit from establishing this test as a clinical and research tool to effectively assess functional capacity.
Authors: Colin A Depp; Brent Mausbach; Eric Granholm; Veronica Cardenas; Dror Ben-Zeev; Thomas L Patterson; Barry D Lebowitz; Dilip V Jeste Journal: J Nerv Ment Dis Date: 2010-10 Impact factor: 2.254
Authors: Dilip V Jeste; Barton W Palmer; Paul S Appelbaum; Shahrokh Golshan; Danielle Glorioso; Laura B Dunn; Kathleen Kim; Thomas Meeks; Helena C Kraemer Journal: Arch Gen Psychiatry Date: 2007-08
Authors: Samir Sabbag; Elizabeth W Twamley; Lea Vella; Robert K Heaton; Thomas L Patterson; Philip D Harvey Journal: Schizophr Res Date: 2012-03-02 Impact factor: 4.939
Authors: C I Cohen; G D Cohen; K Blank; C Gaitz; I R Katz; A Leuchter; G Maletta; B Meyers; K Sakauye; C Shamoian Journal: Am J Geriatr Psychiatry Date: 2000 Impact factor: 4.105
Authors: Russell M Bauer; Grant L Iverson; Alison N Cernich; Laurence M Binder; Ronald M Ruff; Richard I Naugle Journal: Clin Neuropsychol Date: 2012-03-07 Impact factor: 3.535
Authors: Brent T Mausbach; Philip D Harvey; Ann E Pulver; Colin A Depp; Paula S Wolyniec; Mary H Thornquist; James R Luke; John A McGrath; Christopher R Bowie; Thomas L Patterson Journal: Bipolar Disord Date: 2010-02 Impact factor: 6.744
Authors: Raeanne C Moore; Pariya L Fazeli; Thomas L Patterson; Colin A Depp; David J Moore; Eric Granholm; Dilip V Jeste; Brent T Mausbach Journal: Schizophr Res Date: 2015-03-16 Impact factor: 4.939
Authors: Samantha K Holden; Luis D Medina; Brian Hoyt; Stefan H Sillau; Brian D Berman; Jennifer G Goldman; Daniel Weintraub; Benzi M Kluger Journal: Mov Disord Date: 2018-10-10 Impact factor: 10.338
Authors: Stacy A Ruse; Vicki G Davis; Alexandra S Atkins; K Ranga R Krishnan; Kolleen H Fox; Philip D Harvey; Richard S E Keefe Journal: J Vis Exp Date: 2014-04-23 Impact factor: 1.355
Authors: Raeanne C Moore; Emily W Paolillo; Anne Heaton; Pariya L Fazeli; Dilip V Jeste; David J Moore Journal: PLoS One Date: 2017-08-24 Impact factor: 3.240
Authors: Shelagh Szabo; Elizabeth Merikle; Greta Lozano-Ortega; Lauren Powell; Thomas Macek; Stephanie Cline Journal: Schizophr Res Treatment Date: 2018-12-27